| Trial ID: | L2618 |
| Source ID: | NCT00127192
|
| Associated Drug: |
Sitagliptin Phosphate
|
| Title: |
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00127192/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: sitagliptin phosphate|DRUG: Comparator: placebo (unspecified)
|
| Outcome Measures: |
Primary: Change From Baseline in HbA1c at Week 12, HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent., Baseline and Week 12 | Secondary: Change From Baseline in Glycosylated Albumin at Week 12, Change from baseline at Week 12 is defined as Week 12 minus Week 0., Baseline and Week 12|Change From Baseline in Fasting Plasma Glucose at Week 12, Change from baseline at Week 12 is defined as Week 12 minus Week 0., Baseline and Week 12
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
363
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-07
|
| Completion Date: |
2006-03
|
| Results First Posted: |
2009-09-25
|
| Last Update Posted: |
2015-06-15
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00127192
|
